Higher levels of autoantibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis than in patients with psoriasis vulgaris

Clinical and Developmental Immunology

Volumn 2013, Issue , 2013, Pages

  Dalmády, Szandra ^a   Kiss, Mária ^a   Képíró, László ^a   Kovács, László ^a   Sonkodi, Gábor ^b   Kemény, Lajos ^a   Gyulai, Rolland ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Erzsébet Hospital   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY TARGETING MUTATED CITRULLINATED VIMENTIN; AUTOANTIBODY; BIOLOGICAL MARKER; METHOTREXATE; SALAZOSULFAPYRIDINE; STEROID; UNCLASSIFIED DRUG; VIMENTIN; CITRULLINE;

ADULT; ANTIBODY TITER; ARTICLE; BIOLOGICAL THERAPY; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NAIL DISEASE; PREVALENCE; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; PUVA; STEROID THERAPY; SYMPTOM; SYSTEMIC THERAPY; ULTRAVIOLET B RADIATION; AGED; BLOOD; CHEMISTRY; GENETICS; HUMORAL IMMUNITY; IMMUNOLOGY; JOINT; MIDDLE AGED; MUTATION; PATHOLOGY; RHEUMATOID ARTHRITIS; SKIN;

ADULT; AGED; ARTHRITIS, PSORIATIC; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOLOGICAL MARKERS; CITRULLINE; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNITY, HUMORAL; JOINTS; MALE; MIDDLE AGED; MUTATION; PREVALENCE; SKIN; VIMENTIN;

MLCS; MLOWN;

EID: 84876536140     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2013/474028     Document Type: Article

References (53)

1. Schellekens G. A., Visser H., de Jong B. A., The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis and Rheumatism 2000 43 1 155 163 (Pubitemid 30368225)
2. Rantapää-Dahlqvist S., de Jong B. A. W., Berglin E., Hallmans G., Wadell G., Stenlund H., Sundin U., van Venrooij W. J., Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis and Rheumatism 2003 48 10 2741 2749 2-s2.0-18744430797 10.1002/art.11223 (Pubitemid 37280601)
3. Lee D. M., Schur P. H., Clinical utility of the anti-CCP assay in patients with rheumatic diseases. Annals of the Rheumatic Diseases 2003 62 9 870 874 2-s2.0-0042386360 10.1136/ard.62.9.870 (Pubitemid 37026499)
4. Klareskog L., Widhe M., Hermansson M., Rönnelid J., Antibodies to citrullinated proteins in arthritis: pathology and promise. Current Opinion in Rheumatology 2008 20 3 300 305 2-s2.0-41549169663 10.1097/BOR.0b013e3282fbd22a (Pubitemid 351483320)
5. Skogh T., Does a positive anti-CCP test identify a distinct arthritis entity? Arthritis Research and Therapy 2005 7 6 230 232 2-s2.0-27844552551 10.1186/ar1836 (Pubitemid 41655699)
6. van Mil A. H. M. V., Huizinga T. W. J., Advances in the genetics of rheumatoid arthritis point to subclassification into distinct disease subsets. Arthritis Research and Therapy 2008 10 2, article 205 2-s2.0-52149095213 10.1186/ar2384
7. van Boekel M. A. M., Vossenaar E. R., van den Hoogen F. H. J., van Venrooij W. J., Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Research 2002 4 2 87 93 2-s2.0-0036199752 10.1186/ar395 (Pubitemid 34257342)
8. Bizzaro N., Mazzanti G., Tonutti E., Villalta D., Tozzoli R., Diagnostic accuracy of the anti-citrulline antibody assay for rheumatoid arthritis. Clinical Chemistry 2001 47 6 I 1089 1093 2-s2.0-0035001202 (Pubitemid 32493596)
9. Vencovsky J., Machacek S., Sedova L., Autoantibodies can be prognostic markers of an erosive disease in early rheumatoid arthritis. Annals of the Rheumatic Diseases 2003 62 5 427 430 2-s2.0-0037404894 10.1136/ard.62.5.427 (Pubitemid 36469733)
10. vander Cruyssen B., Peene I., Cantaert T., Hoffman I. E. A., de Rycke L., Veys E. M., de Keyser F., Anti-citrullinated protein/peptide antibodies (ACPA) in rheumatoid arthritis: specificity and relation with rheumatoid factor. Autoimmunity Reviews 2005 4 7 468 474 2-s2.0-24044511806 10.1016/j.autrev.2005. 04.018 (Pubitemid 41219326)
11. Visser H., le Cessie S., Vos K., Breedveld F. C., Hazes J. M. W., How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis and Rheumatism 2002 46 2 357 365 2-s2.0-0036166309 10.1002/art.10117 (Pubitemid 34136572)
12. Kroot E. J., de Jong B. A., van Leeuwen M. A., The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis and Rheumatism 2000 43 8 1831 1835
13. van Jaarsveld C. H. M., ter Borg E. J., Jacobs J. W. G., Schellekens G. A., Gmelig-Meyling F. H. J., van Booma-Frankfort C., de Jong B. A. W., van Venrooij W. J., Bijlsma J. W. J., The prognostic value of the antiperinuclear factor, anti-citrullinated peptide antibodies and rheumatoid factor in early rheumatoid arthritis. Clinical and Experimental Rheumatology 1999 17 6 689 697 2-s2.0-0032699451
14. Anzilotti C., Merlini G., Pratesi F., Tommasi C., Chimenti D., Migliorini P., Antibodies to viral citrullinated peptide in rheumatoid arthritis. Journal of Rheumatology 2006 33 4 647 651 2-s2.0-33645823916
15. Pratesi F., Tommasi C., Anzilotti C., Puxeddu I., Sardano E., di Colo G., Migliorini P., Antibodies to a new viral citrullinated peptide, VCP2: fine specificity and correlation with anti-cyclic citrullinated peptide (CCP) and anti-VCP1 antibodies. Clinical and Experimental Immunology 2011 164 3 337 345 2-s2.0-79955424299 10.1111/j.1365-2249.2011.04378.x
16. Bartoloni E., Alunno A., Bistoni O., Diagnostic value of anti-mutated citrullinated vimentin in comparison to anti-cyclic citrullinated peptide and anti-viral citrullinated peptide 2 antibodies in rheumatoid arthritis: an Italian multicentric study and review of the literature. Autoimmunity Reviews 2012 11 11 815 820
17. Bang H., Egerer K., Gauliard A., Lüthke K., Rudolph P. E., Fredenhagen G., Berg W., Feist E., Burmester G. R., Mutation and citrullination modifies vimentin to a novel autoantigen for rheumatoid arthritis. Arthritis and Rheumatism 2007 56 8 2503 2511 2-s2.0-34547785469 10.1002/art.22817 (Pubitemid 47237269)
18. Damjanovska L., Thabet M. M., Levarth E. W. N., Stoeken-Rijsbergen G., van der Voort E. I., Toes R. E. M., Huizinga T. W. J., van Mil A. H. M. V., Diagnostic value of anti-MCV antibodies in differentiating early inflammatory arthritis. Annals of the Rheumatic Diseases 2010 69 4 730 732 2-s2.0-77950315397 10.1136/ard.2009.108456
19. Mathsson L., Mullazehi M., Wick M. C., Sjöberg O., van Vollenhoven R., Klareskog L., Rönnelid J., Antibodies against citrullinated vimentin in rheumatoid arthritis: higher sensitivity and extended prognostic value concerning future radiographic progression as compared with antibodies against cyclic citrullinated peptides. Arthritis and Rheumatism 2008 58 1 36 45 2-s2.0-38149026334 10.1002/art.23188
20. Soós L., Szekanecz Z., Szabó Z., Fekete A., Zeher M., Horváth I. F., Dankó K., Kapitány A., Végvári A., Sipka S., Szegedi G., Lakos G., Clinical evaluation of anti-mutated citrullinated vimentin by ELISA in rheumatoid arthritis. Journal of Rheumatology 2007 34 8 1658 1663 2-s2.0-34547946602 (Pubitemid 47267606)
21. Mansour H. E., Metwaly K. M., Hassan I. A., Elshamy H. A. A., Elbeblawy M. M. S., Antibodies to mutated citrullinated vimentin in rheumatoid arthritis: diagnostic value, association with radiological damage and axial skeleton affection. Clinical Medicine Insights 2010 3 33 42 2-s2.0-77955378365
22. Vossenaar E. R., Després N., Lapointe E., van der Heijden A., Lora M., Senshu T., van Venrooij W. J., Ménard H. A., Rheumatoid arthritis specific anti-Sa antibodies target citrullinated vimentin. Arthritis Research and Therapy 2004 6 2 R142 R150 2-s2.0-1842619397
23. Ménard H. A., Lapointe E., Rochdi M. D., Zhou Z. J., Insights into rheumatoid arthritis derived from the Sa immune system. Arthritis Research 2000 2 6 429 432 2-s2.0-0034467068 10.1186/ar122 (Pubitemid 32223782)
24. Wagner E., Skoumal M., Bayer P. M., Klaushofer K., Antibody against mutated citrullinated vimentin: a new sensitive marker in the diagnosis of rheumatoid arthritis. Rheumatology International 2009 29 11 1315 1321 2-s2.0-69049098891 10.1007/s00296-009-0854-2
25. Gottenberg J. E., Mignot S., Nicaise-Rolland P., Cohen-Solal J., Aucouturier F., Goetz J., Labarre C., Meyer O., Sibilia J., Mariette X., Prevalence of anti-cyclic citrullinated peptide and anti-keratin antibodies in patients with primary Sjögren's syndrome. Annals of the Rheumatic Diseases 2005 64 1 114 117 2-s2.0-19944428399 10.1136/ard.2003.019794 (Pubitemid 40075286)
26. Avčin T., Meroni P. L., Cimaz R., Falcini F., Zulian F., Martini G., Simonini G., Porenta-Bešic V., Cecchini G., Borghi M. O., Prevalence and clinical significance of anti-cyclic citrullinated peptide antibodies in juvenile idiopathic arthritis. Annals of the Rheumatic Diseases 2002 61 7 608 611 2-s2.0-0036288237 10.1136/ard.61.7.608 (Pubitemid 34717771)
27. Mediwake R., Isenberg D. A., Schellekens G. A., van Venrooij W. J., Use of anti-citrullinated peptide and anti-RA33 antibodies in distinguishing erosive arthritis in patients with systemic lupus erythematosus and rheumatoid arthritis. Annals of the Rheumatic Diseases 2001 60 1 67 68 2-s2.0-0035165081 10.1136/ard.60.1.67 (Pubitemid 32038957)
28. Rahman P., Elder J. T., Genetic epidemioloqy of psoriasis and psoriatic arthritis. Annals of the Rheumatic Diseases 2005 64 supplement 2 ii37 ii40 2-s2.0-14244255488 10.1136/ard.2004.030775 (Pubitemid 40288518)
29. Marsal S., Armadans-Gil L., Martínez M., Gallardo D., Ribera A., Lience E., Clinical, radiographic and HLA associations as markers for different patterns of psoriatic arthritis. Rheumatology 1999 38 4 332 337 2-s2.0-0032731387 10.1093/rheumatology/38.4.332 (Pubitemid 29507183)
30. Liu Y., Helms C., Liao W., Zaba L. C., Duan S., Gardner J., Wise C., Miner A., Malloy M. J., Pullinger C. R., Kane J. P., Saccone S., Worthington J., Bruce I., Kwok P. Y., Menter A., Krueger J., Barton A., Saccone N. L., Bowcock A. M., A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genetics 2008 4 3 e1000041 2-s2.0-44949172789 10.1371/journal.pgen.1000041 (Pubitemid 351656703)
31. Gladman D. D., Shuckett R., Russell M. L., Psoriatic arthritis (PSA)-an analysis of 220 patients. Quarterly Journal of Medicine 1987 62 238 127 141 2-s2.0-0023107243 (Pubitemid 17042878)
32. Alonso J. C. T., Perez A. R., Castrillo J. M. A., Garcia J. B., Noriega J. L. R., Larrea C. L., Psoriatic arthritis (PA): a clinical, immunological and radiological study of 180 patients. British Journal of Rheumatology 1991 30 4 245 250 2-s2.0-0025800559
33. Gladman D. D., Helliwell P., Mease P. J., Nash P., Ritchlin C., Taylor W., Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis and Rheumatism 2004 50 1 24 35 2-s2.0-0346458589 10.1002/art.11417 (Pubitemid 38084284)
34. McGonagle D., Conaghan P. G., Emery P., Psoriatic arthritis: a unified concept twenty years on. Arthritis and Rheumatism 1999 42 6 1080 1086 (Pubitemid 29268943)
35. Veale D., Rogers S., FitzGerald O., Classification of clinical subsets in psoriatic arthritis. British Journal of Rheumatology 1994 33 2 133 138 2-s2.0-0027955027 (Pubitemid 24051604)
36. Taylor W., Gladman D., Helliwell P., Marchesoni A., Mease P., Mielants H., Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis and Rheumatism 2006 54 8 2665 2673 2-s2.0-33746951437 10.1002/art.21972 (Pubitemid 44205029)
37. Moll J. M. H., Wright V., Psoriatic arthritis. Seminars in Arthritis and Rheumatism 1973 3 1 55 78 2-s2.0-0015799817 10.1016/0049-0172(73)90035-8
38. Prevoo M. L. L., van 't Hof M. A., Kuper H. H., van Leeuwen M. A., van de Putte L. B. A., van Riel P. L. C. M., Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis and Rheumatism 1995 38 1 44 48 2-s2.0-0028815803 10.1002/art.1780380107
39. Wells G., Becker J. C., Teng J., Dougados M., Schiff M., Smolen J., Aletaha D., van Riel P. L. C. M., Validation of the 28-joint Disease Activity Score (DAS28) and European League against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. Annals of the Rheumatic Diseases 2009 68 6 954 960 2-s2.0-67449116863 10.1136/ard.2007.084459
40. Fredriksson T., Pettersson U., Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978 157 4 238 244 2-s2.0-0018099294 (Pubitemid 8387357)
41. Tesija-Kuna A., Grazio S., Miler M., Vukasovic I., Peric P., Vrkic N., Antibodies targeting mutated citrullinated vimentin in patients with psoriatic arthritis. Clinical Rheumatology 2010 29 5 487 493 2-s2.0-77950866412 10.1007/s10067-009-1345-2
42. Bodnar N., Szekanecz Z., Prohaszka Z., Anti-mutated citrullinated vimentin (anti-MCV) and anti-65 kDa heat shock protein (anti-hsp65): new biomarkers in ankylosing spondylitis. Joint, Bone, Spine 2012 79 1 63 66
43. McGonagle D., Enthesitis: an autoinflammatory lesion linking nail and joint involvement in psoriatic disease. Journal of the European Academy of Dermatology and Venereology 2009 23 supplement 1 9 13 2-s2.0-69049090902 10.1111/j.1468-3083.2009.03363.x
44. Ash Z. R., Tinazzi I., Gallego C. C., Psoriasis patients with nail disease have a greater magnitude of underlying systemic subclinical enthesopathy than those with normal nails. Annals of the Rheumatic Diseases 2012 71 4 553 556
45. Chen H. A., Lin K. C., Chen C. H., Liao H. T., Wang H. P., Chang H. N., Tsai C. Y., Chou C. T., The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases 2006 65 1 35 39 2-s2.0-29144519684 10.1136/ard.2005.038851 (Pubitemid 41815636)
46. Alessandri C., Bombardieri M., Papa N., Cinquini M., Magrini L., Tincani A., Valesini G., Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNF therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. Annals of the Rheumatic Diseases 2004 63 10 1218 1221 2-s2.0-1942440157 10.1136/ard.2003.014647 (Pubitemid 39273496)
47. Braun-Moscovici Y., Markovits D., Zinder O., Schapira D., Rozin A., Ehrenburg M., Dain L., Hoffer E., Nahir A. M., Balbir-Gurman A., Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-therapy in patients with rheumatoid arthritis. Journal of Rheumatology 2006 33 3 497 500 2-s2.0-33644698605 (Pubitemid 43334571)
48. Nicaise Roland P., Grootenboer Mignot S., Bruns A., Hurtado M., Palazzo E., Hayem G., Dieudé P., Meyer O., Martin S. C., Antibodies to mutated citrullinated vimentin for diagnosing rheumatoid arthritis in anti-CCP-negative patients and for monitoring infliximab therapy. Arthritis Research and Therapy 2008 10 6 R142 2-s2.0-67949091264
49. Caramaschi P., Biasi D., Tonolli E., Pieropan S., Martinelli N., Carletto A., Volpe A., Bambara L. M., Antibodies against cyclic citrullinated peptides in patients affected by rheumatoid arthritis before and after infliximab treatment. Rheumatology International 2005 26 1 58 62 2-s2.0-24044553794 10.1007/s00296-004-0571-9 (Pubitemid 41531516)
50. de Rycke L., Verhelst X., Kruithof E., van den Bosch F., Hoffman I. E. A., Veys E. M., de Keyser F., Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. Annals of the Rheumatic Diseases 2005 64 2 299 302 2-s2.0-13244261140 10.1136/ard.2004.023523 (Pubitemid 40193631)
51. Bobbio-Pallavicini F., Caporali R., Alpini C., Avalle S., Epis O. M., Klersy C., Montecucco C., High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor inhibitors in rheumatoid arthritis. Annals of the Rheumatic Diseases 2007 66 3 302 307 2-s2.0-34147220774 10.1136/ard.2006.060608 (Pubitemid 46579628)
52. Elder J. T., Genome-wide association scan yields new insights into the immunopathogenesis of psoriasis. Genes and Immunity 2009 10 3 201 209 2-s2.0-67349236684 10.1038/gene.2009.11
53. Queiro R., Alonso S., Alperi M., Fernández M., Sarasqueta C., Stratification by age of onset with 30 years as age limit is an effective means of identifying PSORS1-associated psoriasis in patients with psoriatic arthritis. Joint, Bone, Spine 2011 78 6 581 583 2-s2.0-79955078026 10.1016/j.jbspin.2011. 02.009